Metastatic Castrate Resistant Prostate Cancer (mCRPC), Prostate Cancer (Adenocarcinoma)
Conditions
Keywords
Mevrometostat, EZH2 inhibitor, Enzalutamide, ARPI resistance, MOMENT, mCRPC, Prostate Cancer
Brief summary
The purpose of this study is to find out whether mevrometostat in combination with enzalutamide delays cancer progression in people with metastatic castration-resistant prostate cancer (mCRPC) who have previously received enzalutamide, darolutamide, or apalutamide in the metastatic castration-sensitive prostate cancer (mCSPC) or non-metastatic castration-resistant prostate cancer (nmCRPC) setting but have not previously progressed on abiraterone.
Interventions
DRUGMevrometostat
875 mg oral tablet, taken twice daily with food
DRUGEnzalutamide
160 mg oral capsule, taken once daily
Sponsors
Prostate Cancer Clinical Trials Consortium
Pfizer
Dana-Farber Cancer Institute
Fred Hutchinson Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Willing and able to provide written informed consent * Age 18 years or older * Diagnosis of prostate cancer (adenocarcinoma) confirmed by tissue sample, without neuroendocrine or small cell features * Currently taking or recently treated with enzalutamide, darolutamide, or apalutamide (within 30 days of screening) and willing to switch to or restart enzalutamide for this study * Cancer has spread to bone or soft tissue (metastatic disease), confirmed by imaging * ECOG performance status of 0, 1, or 2 (able to care for self and up and about more than 50% of waking hours) * Testosterone level less than 50 ng/dL at screening, with ongoing hormone deprivation therapy or prior surgical castration * If receiving bone-protective therapy (e.g., denosumab or bisphosphonates), must be on a stable dose for at least 4 weeks * Evidence of cancer progression while on enzalutamide, darolutamide, or apalutamide, shown by rising PSA, worsening disease on imaging, or new bone lesions * Adequate organ function based on blood tests within 28 days of starting treatment, including adequate blood counts, kidney function, and liver function * Willing to use acceptable birth control during the study and for 30 days after the last dose
Exclusion criteria
* History of myelodysplastic syndrome, acute myeloid leukemia, or other prior cancer (exceptions: non-melanoma skin cancer, carcinoma in situ, cancers more than 3 years ago with no recurrence, or early-stage cancers with low risk of recurrence) * Any medical or psychiatric condition, including active infection or recent suicidal ideation, that may make study participation unsafe * History of seizure or conditions that may increase seizure risk (e.g., prior stroke, significant brain trauma), or loss of consciousness or transient ischemic attack within 12 months * Untreated brain metastases, spinal cord compression, or clinically significant epidural disease * Use of 5-alpha reductase inhibitors, herbal medications, or supplements known to alter PSA levels within 4 weeks of starting treatment * AIDS-related illness or active hepatitis B or C (well-controlled HIV is allowed) * Known history of chronic liver disease (e.g., alcoholic liver disease, primary biliary cirrhosis, autoimmune hepatitis, Wilson's disease, hemochromatosis) * Known history of active inflammatory gastrointestinal disease, chronic diarrhea, or prior gastric resection or lap-band surgery * Clinically significant cardiovascular disease within the past 6 months (e.g., heart attack, unstable angina, stroke, heart failure NYHA Class III/IV, pulmonary embolism, significant arrhythmias), cardiac pacemaker, or QTcF greater than 480 msec on screening ECG * Prior or current use of PARP inhibitors and/or AKT inhibitors * Prior cancer progression on abiraterone (stopping abiraterone due to side effects is allowed) * Known allergy to any study drug * Blood transfusion within 28 days prior to screening blood tests * Use of another investigational drug within 4 weeks before starting study treatment * Any other condition that, in the opinion of the investigator, would prevent safe participation * Current use or anticipated need for strong CYP3A4/5 inhibitors or inducers (other than enzalutamide) within 10 days or 5 half-lives prior to treatment start
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Radiographic progression free survival (rPFS) | From treatment initiation until documented disease progression, death, lost to follow-up, withdrawal, administrative censoring at the time of final analysis, whichever comes first, assessed up to 24 months. | rPFS by RECIST v1.1 and PCWG3 defined as time from start of study treatment to the earlier of first documentation of objective progressive disease by RECIST v1.1 or PCWG3 or death due to any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Participants Achieving 50% Decline in PSA (PSA50 Response) | From initiation of study treatment through study completion, assessed up to 24 months. | Proportion of participants with detectable PSA values at baseline with a 50% decline in PSA confirmed by a subsequent PSA value obtained ≥3 weeks later. |
| Time to PSA Progression as Defined by PCWG3 | From start of study treatment until documented PSA progression, assessed up to 24 months. | Time from first dose of mevrometostat to the date of a ≥25% increase in PSA over nadir with an absolute increase of ≥2 ng/mL, confirmed by a second consecutive PSA value at ≥3 weeks later. |
| Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v5.0 | From start of study treatment through 28 days after last dose of study drug, assessed up to 24 months. | Incidence of adverse events characterized by type, severity according to CTCAE version 5.0, timing, seriousness, and relationship to study treatment. |
| Overall Survival (OS) | From start of study treatment until death from any cause, assessed up to 24 months. | Overall survival as determined by survival status during study participation. OS is defined as the time from the start of study treatment to the date of death due to any cause. |
Contacts
CONTACTSarah Wise
PRINCIPAL_INVESTIGATORMichael Schweizer, MD
University of Washington- Fred Hutch Cancer Center
PRINCIPAL_INVESTIGATORAtish Choudhury, MD, PhD
Dana-Farber Cancer Institute
Outcome results
None listed